$CARM
Carisma Therapeutics Inc.

2015 Q2 Form 10-Q Financial Statement

#000148500315000005 Filed on August 13, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q2
Revenue $114.0K $761.0K
YoY Change -85.02% 276.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.250M $2.050M
YoY Change 9.76% 132.95%
% of Gross Profit
Research & Development $6.269M $6.754M
YoY Change -7.18% 149.78%
% of Gross Profit
Depreciation & Amortization $90.00K $110.0K
YoY Change -18.18% 0.0%
% of Gross Profit
Operating Expenses $8.516M $8.806M
YoY Change -3.29% 145.63%
Operating Profit -$8.402M -$8.045M
YoY Change 4.44% 137.81%
Interest Expense -$330.0K -$79.00K
YoY Change 317.72% -42.34%
% of Operating Profit
Other Income/Expense, Net $1.496M -$76.00K
YoY Change -2068.42% -69.72%
Pretax Income -$6.910M -$8.120M
YoY Change -14.9% 123.69%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.906M -$8.121M
YoY Change -14.96% 123.47%
Net Earnings / Revenue -6057.89% -1067.15%
Basic Earnings Per Share
Diluted Earnings Per Share -$362.0K -$505.6K
COMMON SHARES
Basic Shares Outstanding 19.37M shares 16.26M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $53.50M $45.00M
YoY Change 18.89% 533.8%
Cash & Equivalents $53.49M $45.03M
Short-Term Investments
Other Short-Term Assets $900.0K $1.000M
YoY Change -10.0% 66.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $54.43M $46.03M
YoY Change 18.25% 497.83%
LONG-TERM ASSETS
Property, Plant & Equipment $580.0K $682.0K
YoY Change -14.96% -31.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $16.00K $15.00K
YoY Change 6.67%
Total Long-Term Assets $690.0K $791.0K
YoY Change -12.77% -20.9%
TOTAL ASSETS
Total Short-Term Assets $54.43M $46.03M
Total Long-Term Assets $690.0K $791.0K
Total Assets $55.12M $46.82M
YoY Change 17.72% 438.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.880M $2.602M
YoY Change -27.75% 271.71%
Accrued Expenses $618.0K $1.140M
YoY Change -45.79% 280.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $2.500M $1.600M
YoY Change 56.25% 23.08%
Total Short-Term Liabilities $5.472M $6.027M
YoY Change -9.21% -10.04%
LONG-TERM LIABILITIES
Long-Term Debt $12.20M $2.100M
YoY Change 480.95% -43.24%
Other Long-Term Liabilities $164.0K $100.0K
YoY Change 64.0% -90.0%
Total Long-Term Liabilities $164.0K $2.200M
YoY Change -92.55% -53.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.472M $6.027M
Total Long-Term Liabilities $164.0K $2.200M
Total Liabilities $5.636M $8.200M
YoY Change -31.27% -28.07%
SHAREHOLDERS EQUITY
Retained Earnings -$105.2M -$72.94M
YoY Change 44.21%
Common Stock $19.00K $16.00K
YoY Change 18.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.22M $38.62M
YoY Change
Total Liabilities & Shareholders Equity $55.12M $46.82M
YoY Change 17.72% 438.21%

Cashflow Statement

Concept 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$6.906M -$8.121M
YoY Change -14.96% 123.47%
Depreciation, Depletion And Amortization $90.00K $110.0K
YoY Change -18.18% 0.0%
Cash From Operating Activities -$9.030M -$8.450M
YoY Change 6.86% 359.24%
INVESTING ACTIVITIES
Capital Expenditures -$260.0K -$80.00K
YoY Change 225.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$260.0K -$80.00K
YoY Change 225.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 17.23M -410.0K
YoY Change -4302.44% -111.82%
NET CHANGE
Cash From Operating Activities -9.030M -8.450M
Cash From Investing Activities -260.0K -80.00K
Cash From Financing Activities 17.23M -410.0K
Net Change In Cash 7.940M -8.940M
YoY Change -188.81% -648.47%
FREE CASH FLOW
Cash From Operating Activities -$9.030M -$8.450M
Capital Expenditures -$260.0K -$80.00K
Free Cash Flow -$8.770M -$8.370M
YoY Change 4.78% 354.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Assets
Assets
55122000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19379285 shares
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
Eleven Biotherapeutics, Inc.
dei Trading Symbol
TradingSymbol
EBIO
ebio Collaborative Arrangement Date Of Agreement
CollaborativeArrangementDateOfAgreement
2013-05-28
ebio Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
56678000 USD
ebio Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
0 USD
ebio Conversion Of Preferred Stock Warrant To Common Stocks Warrants
ConversionOfPreferredStockWarrantToCommonStocksWarrants
247000 USD
ebio Conversion Of Preferred Stock Warrant To Common Stocks Warrants
ConversionOfPreferredStockWarrantToCommonStocksWarrants
0 USD
CY2015Q2 ebio Estimated Milestone Payment To Be Received
EstimatedMilestonePaymentToBeReceived
25000000 USD
ebio Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0 USD
ebio Research Term
ResearchTerm
P30Y
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2458000 USD
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1880000 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1987000 USD
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
618000 USD
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
195000 USD
CY2015Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
224000 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
128558000 USD
CY2015Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
142380000 USD
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22000 USD
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1668157 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3269884 shares
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Interest Paid
InterestPaid
123000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
54401000 USD
us-gaap Interest Paid
InterestPaid
374000 USD
CY2014Q4 us-gaap Assets
Assets
55000000 USD
CY2015Q2 us-gaap Assets Current
AssetsCurrent
54432000 USD
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
54059000 USD
CY2015Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
53494000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7942000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45031000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54059000 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53494000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
54059000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
53494000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
37089000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-565000 USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17933260 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19307975 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17933260 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19307975 shares
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
18000 USD
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
19000 USD
CY2014Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
834000 USD
CY2015Q2 us-gaap Construction Payable Current
ConstructionPayableCurrent
179000 USD
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
506000 USD
CY2015Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
451000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
209000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
192000 USD
CY2014Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
3219000 USD
CY2015Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
96000 USD
CY2014Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3219000 USD
CY2015Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
96000 USD
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-510.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.23
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
874000 USD
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
125000 USD
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6000000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M9D
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
500000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-50000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3123000 USD
CY2014 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
913000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
596000 USD
CY2014Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-79000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-163000 USD
CY2015Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-330000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-565000 USD
CY2014 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y11M1D
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y5M1D
CY2014 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.5679
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.6317
CY2014 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0110
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0064
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2052000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3990000 USD
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2247000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4850000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1706000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-578000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
468000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1209000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-715000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-55000 USD
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
84000 USD
CY2015Q2 us-gaap Interest Payable Current
InterestPayableCurrent
88000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55000000 USD
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55122000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5202000 USD
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5472000 USD
CY2014Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
3219000 USD
CY2015Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
96000 USD
CY2014Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9749000 USD
CY2015Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
12171000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
50704000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
17228000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-132000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-286000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13483000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17507000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-8121000 USD
us-gaap Net Income Loss
NetIncomeLoss
-15343000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-6906000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13430000 USD
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8121000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15862000 USD
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6906000 USD
CY2015Q2 us-gaap Proceeds From Royalties Received
ProceedsFromRoyaltiesReceived
0 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8045000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-15234000 USD
CY2015Q2 us-gaap Notes Payable Current
NotesPayableCurrent
2523000 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
8806000 USD
us-gaap Operating Expenses
OperatingExpenses
16563000 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
8516000 USD
us-gaap Operating Expenses
OperatingExpenses
16357000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8402000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-15999000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13430000 USD
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
0 shares
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
328000 shares
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-76000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-109000 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1496000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2569000 USD
CY2014Q4 us-gaap Notes Payable Current
NotesPayableCurrent
251000 USD
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 USD
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2000 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19000 USD
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16000 USD
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4000 USD
CY2015Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
164000 USD
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
54000 USD
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1826000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3134000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
18000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
26000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
132000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
286000 USD
CY2014Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 USD
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
519000 USD
CY2015Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 USD
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 USD
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
342000 USD
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
938000 USD
us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
1750000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51505000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12172000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12573000 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6269000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11507000 USD
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
94000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
56000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
486000 USD
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
580000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
833000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6754000 USD
CY2015Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
94000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91750000 USD
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105180000 USD
CY2014Q2 us-gaap Revenues
Revenues
761000 USD
us-gaap Revenues
Revenues
1329000 USD
CY2015Q2 us-gaap Revenues
Revenues
114000 USD
us-gaap Revenues
Revenues
358000 USD
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
501000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1137000 USD
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
602000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1266000 USD
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
740977 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
54608 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
744328 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1438528 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2060334 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.93
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.48
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1733902 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.90
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.80
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.77
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M2D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M10D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M1D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M10D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
67914 shares
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
36826000 USD
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
37219000 USD
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16055000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13000 shares
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19087000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18532000 shares

Files In Submission

Name View Source Status
0001485003-15-000005-index-headers.html Edgar Link pending
0001485003-15-000005-index.html Edgar Link pending
0001485003-15-000005.txt Edgar Link pending
0001485003-15-000005-xbrl.zip Edgar Link pending
acphase3a01.jpg Edgar Link pending
ebio-063015x10q.htm Edgar Link pending
ebio-063015x311.htm Edgar Link pending
ebio-063015x312.htm Edgar Link pending
ebio-063015x321.htm Edgar Link pending
ebio-20150630.xml Edgar Link completed
ebio-20150630.xsd Edgar Link pending
ebio-20150630_cal.xml Edgar Link unprocessable
ebio-20150630_def.xml Edgar Link unprocessable
ebio-20150630_lab.xml Edgar Link unprocessable
ebio-20150630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending